NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$135.4m

Last Updated

2021/04/11 23:51 UTC

Data Sources

Company Financials +

Executive Summary

Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. More Details


Snowflake Analysis

Adequate balance sheet with concerning outlook.


Similar Companies

Share Price & News

How has Aziyo Biologics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AZYO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: AZYO's weekly volatility (9%) has been stable over the past year.


Market Performance


7 Day Return

-5.2%

AZYO

-2.2%

US Biotechs

2.1%

US Market


1 Year Return

n/a

AZYO

31.5%

US Biotechs

56.3%

US Market

Return vs Industry: Insufficient data to determine how AZYO performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how AZYO performed against the US Market.


Shareholder returns

AZYOIndustryMarket
7 Day-5.2%-2.2%2.1%
30 Day-4.3%-4.2%2.4%
90 Day-8.9%-5.5%6.1%
1 Yearn/a33.6%31.5%59.1%56.3%
3 Yearn/a26.9%21.1%65.7%55.1%
5 Yearn/a40.2%29.9%122.3%97.6%

Long-Term Price Volatility Vs. Market

How volatile is Aziyo Biologics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Aziyo Biologics undervalued compared to its fair value and its price relative to the market?

6.5x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AZYO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate AZYO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AZYO is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: AZYO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AZYO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AZYO is overvalued based on its PB Ratio (6.5x) compared to the US Biotechs industry average (3.9x).


Future Growth

How is Aziyo Biologics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

53.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AZYO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AZYO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AZYO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AZYO's revenue (16.8% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: AZYO's revenue (16.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AZYO's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Aziyo Biologics performed over the past 5 years?

-111.8%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: AZYO is currently unprofitable.

Growing Profit Margin: AZYO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if AZYO's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare AZYO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AZYO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.3%).


Return on Equity

High ROE: AZYO has a negative Return on Equity (-104.77%), as it is currently unprofitable.


Financial Health

How is Aziyo Biologics's financial position?


Financial Position Analysis

Short Term Liabilities: AZYO's short term assets ($59.7M) exceed its short term liabilities ($26.8M).

Long Term Liabilities: AZYO's short term assets ($59.7M) exceed its long term liabilities ($35.2M).


Debt to Equity History and Analysis

Debt Level: AZYO's debt to equity ratio (147.1%) is considered high.

Reducing Debt: Insufficient data to determine if AZYO's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AZYO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: AZYO has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 41.1% each year.


Dividend

What is Aziyo Biologics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AZYO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AZYO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AZYO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AZYO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AZYO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.5yrs

Average management tenure


CEO

Ron Lloyd (59 yo)

2.83yrs

Tenure

US$689,215

Compensation

Mr. Ronald K. Lloyd, also known as Ron, has been President, Chief Executive Officer and Director of Aziyo Biologics, Inc. from June 2018. Mr. Lloyd served as Executive Vice President and President of Hospi...


CEO Compensation Analysis

Compensation vs Market: Ron's total compensation ($USD689.22K) is above average for companies of similar size in the US market ($USD510.93K).

Compensation vs Earnings: Insufficient data to compare Ron's compensation with company performance.


Leadership Team

Experienced Management: AZYO's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Members

Experienced Board: AZYO's board of directors are considered experienced (4.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: AZYO only recently listed within the past 12 months.


Top Shareholders

Company Information

Aziyo Biologics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Aziyo Biologics, Inc.
  • Ticker: AZYO
  • Exchange: NasdaqGM
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$135.394m
  • Shares outstanding: 10.23m
  • Website: https://www.aziyo.com

Number of Employees


Location

  • Aziyo Biologics, Inc.
  • 12510 Prosperity Drive
  • Suite 370
  • Silver Spring
  • Maryland
  • 20904
  • United States

Listings


Biography

Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, an...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/11 23:51
End of Day Share Price2021/04/09 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.